Adrenergic modulation of ovarian cancer progression and chemoresistance
卵巢癌进展和化疗耐药的肾上腺素调节
基本信息
- 批准号:9770783
- 负责人:
- 金额:$ 7.57万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至
- 项目状态:未结题
- 来源:
- 关键词:Adenosine MonophosphateAdrenergic AgentsAffectAftercareApoptosisAttenuatedAutomobile DrivingBRCA1 ProteinBRCA1 geneBiologicalBiologyBreastCDKN1C geneCancer BiologyCancer CenterCancer PatientCancer cell lineCancer-Predisposing GeneCardiovascular PathologyCatecholaminesCellsChronic stressCisplatinClinicalCodeCognitive TherapyCyclic AMPCyclic AMP-Dependent Protein KinasesCyclin-Dependent Kinase InhibitorDNA DamageDNA NucleotidylexotransferaseDNA RepairDataDepressed moodDiseaseDistressEmotionalEpinephrineExhibitsFutureGene ExpressionGenerationsGenesGenomicsGoalsGrowthHealth SciencesHormonesInfiltrationInflammatoryJointsLabelLeadLinkMaintenanceMalignant NeoplasmsMalignant neoplasm of ovaryMediatingMessenger RNANerveNorepinephrineOutcomeOvarianOvarian Serous AdenocarcinomaPathway interactionsPatient Self-ReportPatientsPeriodicityPlatinumRegulationResearchResistanceRiskRisk FactorsRoleSignal TransductionSocial supportStressSympathetic Nervous SystemTestingTranscriptional RegulationTumor BiologyTumor InitiatorsUniversitiesWorkbasecancer biomarkerscancer cellchemotherapychronic depressioncytokinedepressive symptomsexperimental studymacrophagemalignant breast neoplasmneoplastic celloutcome forecastperceived stressprecision medicineprotein expressionpsychologicpsychosocialresponsesocialsymptomatologytranscriptometumortumor microenvironmenttumor progression
项目摘要
PROJECT SUMMARY/ABSTRACT
There is growing evidence for the role of stress in cardiovascular pathologies, cancer, and other diseases.
Work from our group and others has shown that psychological states such as chronic stress or depression may
accelerate growth of existing tumors and promote chemoresistance. Importantly, a significant number of
ovarian cancer patients are clinically depressed or lack social support. These emotional states have been
linked to sustained activation of the sympathetic nervous system and decreased survival. Our group has
shown that activation of the sympathetic nervous system leads to increased levels of norepinephrine and
epinephrine in the tumor microenvironment and ovarian cancer progression by inducing pro-tumoral pathways.
Our preliminary data in cancer cell lines suggest that norepinephrine significantly changes the expression of
genes implicated in ovarian cancer and attenuates cisplatin-induced ovarian cancer cell apoptosis. Given the
importance of BRCA1-regulated DNA repair mechanisms in cisplatin response, adrenergic regulation of
BRCA1 expression in tumors may also impact ovarian cancer progression and resistance to platinum-based
therapy. However, the underlying mechanisms behind these observations are not completely understood. In
this pilot we will test this hypothesis by achieving the following aims: 1) To dissect the effects of adrenergic
signaling in ovarian cancer cells and 2) To explore the association between perceived stress and depressive
symptomatology with tumor catecholamines, DNA damage, and BRCA1 protein expression. This proposal
provides a unique approach to explore the link between stress and ovarian cancer outcomes at both the tumor
level and the patient level. This proposal will provide the groundwork for additional research on precision
medicine by linking psychological risk factors with underlying tumor biology.
项目总结/摘要
越来越多的证据表明压力在心血管疾病、癌症和其他疾病中的作用。
我们小组和其他人的工作表明,心理状态,如慢性压力或抑郁,
加速现有肿瘤的生长并促进化学抗性。重要的是,
卵巢癌患者临床上抑郁或缺乏社会支持。这些情绪状态
与交感神经系统的持续激活和生存率下降有关。我们集团
显示交感神经系统的激活导致去甲肾上腺素水平的增加,
肾上腺素在肿瘤微环境和卵巢癌的进展诱导促肿瘤途径。
我们在癌细胞系中的初步数据表明,去甲肾上腺素显著改变了
与卵巢癌有关的基因,并减弱顺铂诱导的卵巢癌细胞凋亡。鉴于
BRCA 1调节的DNA修复机制在顺铂反应、肾上腺素能调节
BRCA 1在肿瘤中的表达也可能影响卵巢癌的进展和对铂类药物的耐药性。
疗法然而,这些观察结果背后的潜在机制尚未完全理解。在
本试验将通过实现以下目标来检验这一假设:1)解剖肾上腺素能神经递质的作用,
卵巢癌细胞中的信号传导; 2)探索感知压力与抑郁之间的关系
肿瘤学与肿瘤儿茶酚胺、DNA损伤和BRCA 1蛋白表达。这项建议
提供了一种独特的方法来探索压力和卵巢癌结果之间的联系,
水平和患者水平。这一提议将为进一步研究精确度奠定基础
将心理风险因素与潜在的肿瘤生物学联系起来。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
GUILLERMO N ARMAIZ-PENA其他文献
GUILLERMO N ARMAIZ-PENA的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('GUILLERMO N ARMAIZ-PENA', 18)}}的其他基金
Mental Health CPR: Transforming Cancer Survivors' Mental Health with Community Participatory Reach for Equity
心理健康心肺复苏:通过社区参与实现公平,改变癌症幸存者的心理健康
- 批准号:
10627065 - 财政年份:2023
- 资助金额:
$ 7.57万 - 项目类别:
Adrenergic signaling inhibition to enhance the immunogenicity of the ovarian tumor microenvironment prior to PD-1 checkpoint therapy
在 PD-1 检查点治疗之前抑制肾上腺素信号传导以增强卵巢肿瘤微环境的免疫原性
- 批准号:
10355862 - 财政年份:2021
- 资助金额:
$ 7.57万 - 项目类别:
Adrenergic signaling inhibition to enhance the immunogenicity of the ovarian tumor microenvironment prior to PD-1 checkpoint therapy
在 PD-1 检查点治疗之前抑制肾上腺素信号传导以增强卵巢肿瘤微环境的免疫原性
- 批准号:
10056699 - 财政年份:2020
- 资助金额:
$ 7.57万 - 项目类别:
The impact of biobehavioral factors and aspirin on ovarian cancer biology
生物行为因素和阿司匹林对卵巢癌生物学的影响
- 批准号:
10761655 - 财政年份:2012
- 资助金额:
$ 7.57万 - 项目类别:
Role of Src in Stress-Mediated Progression of Ovarian Cancer
Src 在压力介导的卵巢癌进展中的作用
- 批准号:
7546613 - 财政年份:2006
- 资助金额:
$ 7.57万 - 项目类别:
Role of Src in Stress-Mediated Progression of Ovarian Cancer
Src 在压力介导的卵巢癌进展中的作用
- 批准号:
7229765 - 财政年份:2006
- 资助金额:
$ 7.57万 - 项目类别:
Role of Src in Stress-Mediated Progression of Ovarian Cancer
Src 在压力介导的卵巢癌进展中的作用
- 批准号:
7385008 - 财政年份:2006
- 资助金额:
$ 7.57万 - 项目类别:
Adrenergic modulation of ovarian cancer progression and chemoresistance
卵巢癌进展和化疗耐药的肾上腺素调节
- 批准号:
9419236 - 财政年份:
- 资助金额:
$ 7.57万 - 项目类别:
相似海外基金
Preclinical test for the efficacy of adrenergic agents in treatment of AD
肾上腺素能药物治疗AD疗效的临床前试验
- 批准号:
8358448 - 财政年份:2012
- 资助金额:
$ 7.57万 - 项目类别:
Preclinical test for the efficacy of adrenergic agents in treatment of AD
肾上腺素能药物治疗AD疗效的临床前试验
- 批准号:
8517552 - 财政年份:2012
- 资助金额:
$ 7.57万 - 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
- 批准号:
7952159 - 财政年份:2009
- 资助金额:
$ 7.57万 - 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
- 批准号:
7952152 - 财政年份:2009
- 资助金额:
$ 7.57万 - 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
- 批准号:
7719194 - 财政年份:2008
- 资助金额:
$ 7.57万 - 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
- 批准号:
7605416 - 财政年份:2007
- 资助金额:
$ 7.57万 - 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
- 批准号:
7605425 - 财政年份:2007
- 资助金额:
$ 7.57万 - 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
- 批准号:
7378753 - 财政年份:2006
- 资助金额:
$ 7.57万 - 项目类别:
Adrenergic Agents for Methamphetamine: Outpatient Trials
甲基苯丙胺肾上腺素药物:门诊试验
- 批准号:
6825160 - 财政年份:2004
- 资助金额:
$ 7.57万 - 项目类别:
ADRENERGIC AGENTS FOR CARDIOPULMONARY RESUSCITATION
用于心肺复苏的肾上腺素能药物
- 批准号:
2702283 - 财政年份:1997
- 资助金额:
$ 7.57万 - 项目类别:














{{item.name}}会员




